Frontlight ResearchEarly access
Multiple myeloma trials in Saudi Arabia
2 of 2 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 3WithdrawnA Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Where
- Riyadh
- Age
- 18 years and over
- People
- 440 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00 - Phase 3Not yet taking people in Saudi ArabiaA Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Where
- Riyadh
- Age
- 18 years to 130 years
- People
- 750 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07735637